The American Society of Clinical Oncology (ASCO) presented its 2017 Advocate of the Year Award to Ray D. Page, DO, PhD, FACOI, for his exceptional advocacy efforts on behalf of individuals living with cancer and their cancer care teams. As a member of the Government Relations Committee and in other roles, Dr. Page has provided distinguished leadership in the society’s policy and advocacy efforts.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
ASCO is now holding Quality Training Program seminars outside of the U.S. for practices interested in participating.
On September 24, 2018, the Food and Drug Administration granted regular approval to duvelisib (COPIKTRA, Verastem, Inc.) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies. In addition, duvelisib received accelerated approval for adult patients with relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies.
Last week, the Food and Drug Administration (FDA) announced a series of critical enforcement actions related to the sale and marketing of e-cigarettes to children and young adults. With the use of e-cigarettes among youth growing at an alarming rate in recent years, the agency has taken record actions to address this challenge and protect youth from the dangers of tobacco products through its Youth Tobacco Prevention Plan.
In the latest ASCO in Action Podcast, Manali Patel, MD, MPH, joined ASCO CEO Dr. Clifford A. Hudis to discuss ASCO’s position statement on Medicaid work requirements, which addresses state waivers submitted to the Centers for Medicare & Medicaid Services (CMS) that, if approved, would make Medicaid eligibility, continued coverage, cost-sharing, and other program benefits dependent on a beneficiary’s work status.
More than 100 oncology care providers from across the United States are heading to Capitol Hill September 25 – 26 to participate in the 2018 ASCO Advocacy Summit. Advocates will meet with Members of Congress and their staff to educate them on critical issues affecting individuals with cancer and their providers, and to encourage lawmakers to support cancer policies that will ensure access to high-quality, high-value cancer care.
ASCO recently hosted a webinar offering an overview of the 2019 Medicare Physician Fee Schedule and Quality Payment Program proposed rule and its potential impact on individuals with cancer. ASCO strongly opposes aspects of the proposed rule that could significantly cut cancer care resources needed to provide high-quality care, and the society urges the Centers for Medicare & Medicaid Services (CMS) to abandon the proposal. ASCO members can still watch this important webinar and view the slides from the presentation.
A new study in the Journal of Oncology Practice surveys practices within ASCO’s Quality Oncology Practice Initiative (QOPI®) to learn about real world implementation and use of Patient Reported Outcomes (PROs). The survey yielded valuable information on the perception of PROs among oncology practices and the data currently being collected.
ASCO is committed to supporting cancer care providers and patients affected by natural disasters with resources and information. Due to the threat of Hurricane Florence, the society has assembled a list of resources to aid cancer patients and care providers in the states and regions affected, including resources provided by the Centers for Medicare and Medicaid Services (CMS), emergency contact information, and information on state societies.
On Sept. 13, 2018, the Food and Drug Administration approved moxetumomab pasudotox-tdfk (LUMOXITITM, AstraZeneca Pharmaceuticals LP), a CD22-directed cytotoxin indicated for adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA).
The American Society of Clinical Oncology (ASCO) today issued a set of recommendations for overcoming financial barriers to patient participation in cancer clinical trials. ASCO’s policy statement, “Addressing Financial Barriers to Patient Participation in Clinical Trials,” stresses the importance of increasing participation in clinical research, especially for patients from particular ethnic/racial, geographic, age, socioeconomic, and other underserved demographic subgroups.
The number of international practices certified in delivering high-quality cancer care based on rigorous standards established by ASCO is increasing. The Medisprof Cancer Center in Romania joins six other practices in Brazil, Greece, and Spain in achieving ASCO’s Quality Oncology Practice Initiative (QOPI®) Certification.
On September 28 from 2–3 p.m. (ET), the National Cancer Institute’s Behavioral Research Program will host a free webinar, “Alcohol and Cancer in the United States,” that will feature ASCO expert Noelle K. LoConte, MD.
The American Society of Clinical Oncology (ASCO) warns that certain provisions of the 2019 Medicare Physician Fee Schedule (MPFS) proposed rule will undermine access to cancer care for Medicare beneficiaries through a combination of payment reductions under the MPFS. In a detailed comment letter to the Centers for Medicare & Medicaid Services (CMS), ASCO fully outlines its concerns with the proposal and recommends specific steps be taken to ensure changes proposed in the rule do not endanger Medicare beneficiary access to cancer care.
CancerLinQ LLC, a wholly owned nonprofit subsidiary ASCO, has announced that Stanford Health Care has signed an agreement to participate in the CancerLinQ® platform. Stanford Health Care includes Stanford Cancer Institute which is designated as a Comprehensive Cancer Center by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH).